The History and Future of Chemotherapy for Melanoma

Hematology/Oncology Clinics of North America

Volumn 23, Issue 3, 2009, Pages 583-597

  Yang, Arvin S ^a   Chapman, Paul B ^a,b  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

Cisplatin; Combination chemotherapy; Dacarbazine; Sorafenib; Temozolomide

Indexed keywords

ALPHA INTERFERON; ALPHA2B INTERFERON; BCG VACCINE; BLEOMYCIN; CARBOPLATIN; CARMUSTINE; CISPLATIN; DACARBAZINE; DOCETAXEL; DOXORUBICIN; FOTEMUSTINE; HYDROXYUREA; IFOSFAMIDE; IRINOTECAN; LOMUSTINE; MELPHALAN; NITROSOUREA; PACLITAXEL; SORAFENIB; TAMOXIFEN; TEMOZOLOMIDE; THALIDOMIDE; TOPOTECAN; VINBLASTINE; VINDESINE;

AREA UNDER THE CURVE; AUTOLOGOUS BONE MARROW TRANSPLANTATION; BLOOD TOXICITY; BONE MARROW SUPPRESSION; BRAIN METASTASIS; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CLINICAL TRIAL; DRUG ACTIVITY; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG MECHANISM; DRUG MEGADOSE; DRUG POTENTIATION; DRUG SAFETY; FATIGUE; FLUID RETENTION; GASTROINTESTINAL TOXICITY; GLIOBLASTOMA; GLIOMA; HUMAN; LOW DRUG DOSE; MELANOMA; METASTASIS; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; MYELOABLATIVE CONDITIONING; NEUTROPENIA; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; THROMBOCYTOPENIA; THROMBOEMBOLISM;

ANGIOGENESIS INHIBITORS; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMOTHERAPY, ADJUVANT; CLINICAL TRIALS, PHASE III AS TOPIC; DRUG THERAPY; FORECASTING; HUMANS; MELANOMA; MULTICENTER STUDIES AS TOPIC; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 65649110504     PISSN: 08898588     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.hoc.2009.03.006     Document Type: Review

References (87)

1. Middleton M.R., Grob J.J., Aaronson N., et al. Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma. J Clin Oncol 18 (2000) 158-166
2. Margolin K., Atkins B., Thompson A., et al. Temozolomide and whole brain irradiation in melanoma metastatic to the brain: a phase II trial of the Cytokine Working Group. J Cancer Res Clin Oncol 128 (2002) 214-218
3. Atkins M.B., Gollob J.A., Sosman J.A., et al. A phase II pilot trial of concurrent biochemotherapy with cisplatin, vinblastine, temozolomide, interleukin 2, and IFN-alpha 2B in patients with metastatic melanoma. Clin Cancer Res 8 (2002) 3075-3081
4. Paul M.J., Summers Y., Calvert A.H., et al. Effect of temozolomide on central nervous system relapse in patients with advanced melanoma. Melanoma Res 12 (2002) 175-178
5. Rietschel P., Wolchok J.D., Krown S., et al. Phase II study of extended-dose temozolomide in patients with melanoma. J Clin Oncol 26 (2008) 2299-2304
6. Hegi M.E., Diserens A.-C., Gorlia T., et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 352 (2005) 997-1003 10.1056/NEJMoa043331
7. Paz M.F., Yaya-Tur R., Rojas-Marcos I., et al. CpG island hypermethylation of the DNA repair enzyme methyltransferase predicts response to temozolomide in primary gliomas. Clin Cancer Res 10 (2004) 4933-4938
8. Ma S., Egyhazi S., Ueno T., et al. O6-methylguanine-DNA-methyltransferase expression and gene polymorphisms in relation to chemotherapeutic response in metastatic melanoma. Br J Cancer 89 (2003) 1517-1523
9. Middleton M.R., Lunn J.M., Morris C., et al. O6-methylguanine-DNA methyltransferase in pretreatment tumour biopsies as a predictor of response to temozolomide in melanoma. Br J Cancer 78 (1998) 1199-1202
10. Ranson M., Hersey P., Thompson D., et al. Randomized trial of the combination of lomeguatrib and temozolomide compared with temozolomide alone in chemotherapy naive patients with metastatic cutaneous melanoma. J Clin Oncol 25 (2007) 2540-2545 10.1200/JCO.2007.10.8217
11. Gajewski T.F., Sosman J., Gerson S.L., et al. Phase II trial of the O6-alkylguanine DNA alkyltransferase inhibitor O6-benzylguanine and 1,3-bis(2-chloroethyl)-1-_nitrosourea in advanced melanoma. Clin Cancer Res 11 (2005) 7861-7865
12. Al-Sarraf M., Fletcher W., Oishi N., et al. Cisplatin hydration with and without mannitol diuresis in refractory disseminated malignant melanoma: a Southwest Oncology Group study. Cancer Treat Rep 66 (1982) 31-35
13. Goodnight Jr. J.E., Moseley H.S., Eilber F.R., et al. cis-Dichlorodiammineplatinum(II) alone and combined with DTIC for treatment of disseminated malignant melanoma. Cancer Treat Rep 63 (1979) 2005-2007
14. Schilcher R.B., Wessels M., Niederle N., et al. Phase II evaluation of fractionated low and single high dose cisplatin in various tumors. J Cancer Res Clin Oncol 107 (1984) 57-60
15. Chary K.K., Higby D.J., Henderson E.S., et al. Phase I study of high-dose cis-dichlorodiammineplatinum(II) with forced diuresis. Cancer Treat Rep 61 (1977) 367-370
16. Steffens T., Bajorin D., Chapman P., et al. A phase II trial of high dose cisplatin and dacarbazine. Cancer 68 (1991) 1230-1237
17. Casper E.S., and Bajorin D. Phase II trial of carboplatin in patients with advanced melanoma. Invest New Drugs 8 (1990) 187-190
18. Chang A., Hunt M., Parkinson D.R., et al. Phase II trial of carboplatin in patients with metastatic malignant melanoma. A report from the Eastern Cooperative Oncology Group. Am J Clin Oncol 16 (1993) 152-155
19. Evans L.M., Casper E.S., and Rosenbluth R. Phase II trial of carboplatin in advanced malignant melanoma. Cancer Treat Rep 71 (1987) 171-172
20. Ramirez G., Wilson W., Grage T., et al. Phase II evaluation of 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU; NSC-409962) in patients with solid tumors. Cancer Chemother Rep 56 (1972) 787-790
21. De Vita V.T., Carbone P.P., Owens Jr. A.H., et al. Clinical trials with 1,3-bis(2-chloroethyl)-1-nitrosourea, NSC-409962. Cancer Res 25 (1965) 1876-1881
22. Luce J.K. Chemotherapy of malignant melanoma. Cancer 30 (1972) 1604-1615
23. Calabresi F., Aapro M., Becquart D., et al. Short report: multicenter phase II trial of the single agent fotemustine in patients with advanced malignant melanoma. Ann Oncol 2 (1991) 377-378
24. Jacquillat C., Khayat D., Banzet P., et al. Final report of the French multicenter phase II study of the nitrosourea fotemustine in 153 evaluable patients with disseminated malignant melanoma including patients with cerebral metastases. Cancer 66 (1990) 1873-1878
25. Kleeberg U.R., Engel E., Israels P., et al. Palliative therapy of melanoma patients with fotemustine. Inverse relationship between tumour load and treatment effectiveness. A multicentre phase II trial of the EORTC-Melanoma Cooperative Group (MCG). Melanoma Res 5 (1995) 195-200
26. Schallreuter K.U., Wenzel E., Brassow F.W., et al. Positive phase II study in the treatment of advanced malignant melanoma with fotemustine. Cancer Chemother Pharmacol 29 (1991) 85-87
27. Avril M.F., Aamdal S., Grob J.J., et al. Fotemustine compared with dacarbazine in patients with disseminated malignant melanoma: a phase III study. J Clin Oncol 22 (2004) 1118-1125
28. Einzig A.I., Schuchter L.M., Recio A., et al. Phase II trial of docetaxel (Taxotere) in patients with metastatic melanoma previously untreated with cytotoxic chemotherapy. Med Oncol 13 (1996) 111-117
29. Bedikian A.Y., Weiss G.R., Legha S.S., et al. Phase II trial of docetaxel in patients with advanced cutaneous malignant melanoma previously untreated with chemotherapy. J Clin Oncol 13 (1995) 2895-2899
30. Aamdal S., Wolff I., Kaplan S., et al. Docetaxel (Taxotere) in advanced malignant melanoma: a phase II study of the EORTC Early Clinical Trials Group. Eur J Cancer 30A (1994) 1061-1064
31. Wiernik P.H., Schwartz E.L., Einzig A., et al. Phase I trial of taxol given as a 24-hour infusion every 21 days: responses observed in metastatic melanoma. J Clin Oncol 5 (1987) 1232-1239
32. Legha S.S., Ring S., Papadopoulos N., et al. A phase II trial of taxol in metastatic melanoma. Cancer 65 (1990) 2478-2481
33. Einzig A.I., Hochster H., Wiernik P.H., et al. A phase II study of taxol in patients with malignant melanoma. Invest New Drugs 9 (1991) 59-64
34. Walker L., Schalch H., King D.M., et al. Phase II trial of weekly paclitaxel in patients with advanced melanoma. Melanoma Res 15 (2005) 453-459
35. Bedikian A.Y., Plager C., Papadopoulos N., et al. Phase II evaluation of paclitaxel by short intravenous infusion in metastatic melanoma. Melanoma Res 14 (2004) 63-66
36. Hochster H., Strawderman M.H., Harris J.E., et al. Conventional dose melphalan is inactive in metastatic melanoma: results of an Eastern Cooperative Oncology Group Study (E1687). Anticancer Drugs 10 (1999) 245-248
37. Negretti E., Ferrari L., Bonfante V., et al. Phase II study with ifosfamide in advanced malignant melanoma. Tumori 74 (1988) 163-165
38. Dumez H., Awada A., Piccart M., et al. A phase I dose-finding clinical pharmacokinetic study of an oral formulation of irinotecan (CPT-11) administered for 5 days every 3 weeks in patients with advanced solid tumours. Ann Oncol 17 (2006) 1158-1165
39. Tas F., Camlica H., Kurul S., et al. Combination chemotherapy with docetaxel and irinotecan in metastatic malignant melanoma. Clin Oncol (R Coll Radiol) 15 (2003) 132-135
40. Janik J.E., Miller L.L., Korn E.L., et al. A prospective randomized phase II trial of GM-CSF priming to prevent topotecan-induced neutropenia in chemotherapy-naive patients with malignant melanoma or renal cell carcinoma. Blood 97 (2001) 1942-1946
41. Kraut E.H., Walker M.J., Staubus A., et al. Phase II trial of topotecan in malignant melanoma. Cancer Invest 15 (1997) 318-320
42. Vorobiof D.A., Rapoport B.L., Mahomed R., et al. Phase II study of pegylated liposomal doxorubicin in patients with metastatic malignant melanoma failing standard chemotherapy treatment. Melanoma Res 13 (2003) 201-203
43. Smylie M.G., Wong R., Mihalcioiu C., et al. A phase II, open label, monotherapy study of liposomal doxorubicin in patients with metastatic malignant melanoma. Invest New Drugs 25 (2007) 155-159
44. Fink W., Zimpfer-Rechner C., Thoelke A., et al. Clinical phase II study of pegylated liposomal doxorubicin as second-line treatment in disseminated melanoma. Onkologie 27 (2004) 540-544
45. Ellerhorst J.A., Bedikian A., Ring S., et al. Phase II trial of doxil for patients with metastatic melanoma refractory to frontline therapy. Oncol Rep 6 (1999) 1097-1099
46. Hwu W.J., Krown S.E., Menell J.H., et al. Phase II study of temozolomide plus thalidomide for the treatment of metastatic melanoma. J Clin Oncol 21 (2003) 3351-3356
47. Hwu W.J., Panageas K.S., Menell J.H., et al. Phase II study of temozolomide plus pegylated interferon-alpha-2b for metastatic melanoma. Cancer 106 (2006) 2445-2451
48. McDermott D.F., Sosman J.A., Gonzalez R., et al. Double-blind randomized phase II study of the combination of sorafenib and dacarbazine in patients with advanced melanoma: a report from the 11715 Study Group. J Clin Oncol 26 (2008) 2178-2185
49. Amaravadi R., Schuchter L.M., McDermott D.F., et al. Updated results of a randomized phase II study comparing two schedules of temozolomide in combination with sorafenib in patients with advanced melanoma. Proc Am Soc Clin Oncol 25 (2007) 8527
50. Del Prete S.A., Maurer L.H., O'Donnell J., et al. Combination chemotherapy with cisplatin, carmustine, dacarbazine, and tamoxifen in metastatic melanoma. Cancer Treat Rep 68 (1984) 1403-1405
51. McClay E.F., Mastrangelo M.J., Berd D., et al. Effective combination chemo/hormonal therapy for malignant melanoma: experience with three consecutive trials. Int J Cancer 50 (1992) 553-556
52. Saba H.I., Cruse C.W., Wells K.E., et al. Treatment of stage IV malignant melanoma with dacarbazine, carmustine, cisplatin, and tamoxifen regimens: a University of South Florida and H. Lee Moffitt Melanoma Center Study. Ann Plast Surg 28 (1992) 65-69
53. Richards J.M., Gilewski T.A., Ramming K., et al. Effective chemotherapy for melanoma after treatment with interleukin-2. Cancer 69 (1992) 427-429
54. Lattanzi S.C., Tosteson T., Chertoff J., et al. Dacarbazine, cisplatin and carmustine, with or without tamoxifen, for metastatic melanoma: 5-year follow-up. Melanoma Res 5 (1995) 365-369
55. Rusthoven J.J., Quirt I.C., Iscoe N.A., et al. Randomized, double-blind, placebo-controlled trial comparing the response rates of carmustine, dacarbazine, and cisplatin with and without tamoxifen in patients with metastatic melanoma. National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 14 (1996) 2083-2090
56. Chapman P.B., Einhorn L.H., Meyers M.L., et al. Phase III multicenter randomized trial of the Dartmouth regimen versus dacarbazine in patients with metastatic melanoma. J Clin Oncol 17 (1999) 2745-2751
57. Middleton M.R., Lorigan P., Owen J., et al. A randomized phase III study comparing dacarbazine, BCNU, cisplatin and tamoxifen with dacarbazine and interferon in advanced melanoma. Br J Cancer 82 (2000) 1158-1162
58. Legha S.S., Ring S., Papadopoulos N., et al. A prospective evaluation of a triple-drug regimen containing cisplatin, vinblastine, and dacarbazine (CVD) for metastatic melanoma. Cancer 64 (1989) 2024-2029
59. Eton O., Legha S.S., Bedikian A.Y., et al. Sequential biochemotherapy versus chemotherapy for metastatic melanoma: results from a phase III randomized trial. J Clin Oncol 20 (2002) 2045-2052
60. Jekunen A.P., Christen R.D., Shalinsky D.R., et al. Synergistic interaction between cisplatin and taxol in human ovarian carcinoma cells in vitro. Br J Cancer 69 (1994) 299-306
61. Hodi F.S., Soiffer R.J., Clark J., et al. Phase II study of paclitaxel and carboplatin for malignant melanoma. Am J Clin Oncol 25 (2002) 283-286
62. Zimpfer-Rechner C., Hofmann U., Figl R., et al. Randomized phase II study of weekly paclitaxel versus paclitaxel and carboplatin as second-line therapy in disseminated melanoma: a multicentre trial of the Dermatologic Co-operative Oncology Group (DeCOG). Melanoma Res 13 (2003) 531-536
63. Stinchcombe T.E., Socinski M.A., Walko C.M., et al. Phase I and pharmacokinetic trial of carboplatin and albumin-bound paclitaxel, ABI-007 (Abraxane) on three treatment schedules in patients with solid tumors. Cancer Chemother Pharmacol 60 (2007) 759-766
64. Flaherty K.T., Schiller J., Schuchter L.M., et al. A phase I trial of the oral, multikinase inhibitor sorafenib in combination with carboplatin and paclitaxel. Clin Cancer Res 14 (2008) 4836-4842
65. Hauschild A, Agarwala SS, Trefzer U, et al. Results of a phase III, randomized, placebo-controlled study of sorafenib in combination with carboplatin and paclitaxel as second-line treatment in patients with unresectable stage III or stage IV melanoma. J Clin Oncol, in press.
66. McElwain T.J., Hedley D.W., Gordon M.Y., et al. High dose melphalan and non-cryopreserved autologous bone marrow treatment of malignant melanoma and neuroblastoma. Exp Hematol 7 Suppl 5 (1979) 360-371
67. Thomas M.R., Robinson W.A., Glode L.M., et al. Treatment of advanced malignant melanoma with high-dose chemotherapy and autologous bone marrow transplantation. Preliminary results-Phase I study. Am J Clin Oncol 5 (1982) 611-622
68. Cornbleet M.A., McElwain T.J., Kumar P.J., et al. Treatment of advanced malignant melanoma with high-dose melphalan and autologous bone marrow transplantation. Br J Cancer 48 (1983) 329-334
69. Lazarus H.M., Herzig R.H., Wolff S.N., et al. Treatment of metastatic malignant melanoma with intensive melphalan and autologous bone marrow transplantation. Cancer Treat Rep 69 (1985) 473-477
70. Wolff S.N., Herzig R.H., Fay J.W., et al. High-dose thiotepa with autologous bone marrow transplantation for metastatic malignant melanoma: results of phase I and II studies of the North American Bone Marrow Transplantation Group. J Clin Oncol 7 (1989) 245-249
71. Shea T.C., Antman K.H., Eder J.P., et al. Malignant melanoma. Treatment with high-dose combination alkylating agent chemotherapy and autologous bone marrow support. Arch Dermatol 124 (1988) 878-884
72. Peters W.P., Eder J.P., Henner W.D., et al. High-dose combination alkylating agents with autologous bone marrow support: a Phase 1 trial. J Clin Oncol 4 (1986) 646-654
73. Tchekmedyian N.S., Tait N., Van Echo D., et al. High-dose chemotherapy without autologous bone marrow transplantation in melanoma. J Clin Oncol 4 (1986) 1811-1818
74. Slease R.B., Benear J.B., Selby G.B., et al. High-dose combination alkylating agent therapy with autologous bone marrow rescue for refractory solid tumors. J Clin Oncol 6 (1988) 1314-1320
75. Antman K., Eder J.P., Elias A., et al. High-dose combination alkylating agent preparative regimen with autologous bone marrow support: the Dana-Farber Cancer Institute/Beth Israel Hospital experience. Cancer Treat Rep 71 (1987) 119-125
76. Thatcher D., Lind M., Morgenstern G., et al. High-dose, double alkylating agent chemotherapy with DTIC, melphalan, or ifosfamide and marrow rescue for metastatic malignant melanoma. Cancer 63 (1989) 1296-1302
77. Corringham R., Gilmore M., Prentice H., et al. High-dose melphalan with autologous bone marrow transplant treatment of poor prognosis tumors. Cancer 52 (1983) 1783-1787
78. Costanzi J.J., Al-Sarraf M., Groope C., et al. Combination chemotherapy plus BCG in the treatment of disseminated malignant melanoma: A Southwest Oncology Group study. Med Pediatr Oncol 10 (1982) 251-258
79. Ringborg U., Rudenstam C.M., Hansson J., et al. Dacarbazine versus dacarbazine-vindesine in disseminated malignant melanoma: a randomized phase II study. Med Oncol Tumor Pharmacother 6 (1989) 285-289
80. Shah G.D., and Chapman P.B. Adjuvant therapy of melanoma. Cancer J 13 (2007) 217-222
81. Veronesi U., Adamus J., Aubert C., et al. A randomized trial of adjuvant chemotherapy and immunotherapy in cutaneous melanoma. N Engl J Med 307 (1982) 913-916
82. Bedikian A.Y., Millward M., Pehamberger H., et al. Bcl-2 antisense (oblimersen sodium) plus dacarbazine in patients with advanced melanoma: the Oblimersen Melanoma Study Group. J Clin Oncol 24 (2006) 4738-4745
83. Costanza M.E., Nathanson L., Schoenfeld D., et al. Results with methyl-CCNU and DTIC in metastatic melanoma. Cancer 40 (1977) 1010-1015
84. Cocconi G., Bella M., Calabresi F., et al. Treatment of metastatic malignant melanoma with dacarbazine plus tamoxifen. N Engl J Med 327 (1992) 516-523
85. Thomson D.B., Adena M., McLeod G.R., et al. Interferon-alpha 2a does not improve response or survival when combined with dacarbazine in metastatic malignant melanoma: results of a multi-institutional Australian randomized trial. Melanoma Res 3 (1993) 133-138
86. Bajetta E., Di Leo A., Zampino M.G., et al. Multicenter randomized trial of dacarbazine alone or in combination with two different doses and schedules of interferon alfa-2a in the treatment of advanced melanoma. J Clin Oncol 12 (1994) 806-811
87. Falkson C.I., Ibrahim J., Kirkwood J.M., et al. Phase III trial of dacarbazine versus dacarbazine with interferon alpha-2b versus dacarbazine with tamoxifen versus dacarbazine with interferon alpha-2b and tamoxifen in patients with metastatic malignant melanoma: an Eastern Cooperative Oncology Group study. J Clin Oncol 16 (1998) 1743-1751